To extend the original assay and establish an AD-specific SAA that can detect both 3R and 4R tau, Kraus and colleagues introduced a point mutation at residue 322 of the AD core (residues 306-378) and tested it as a substrate across a series of pathology confirmed brain samples from different tauopathies [77]. Here, MAPT is linked to Alzheimer disease.